Table 1 Assessment of fibrosis in livers treated with CCl4.

From: Utility of Translocator Protein (18 kDa) as a Molecular Imaging Biomarker to Monitor the Progression of Liver Fibrosis

 

n

Fibrosis score

Percentage of fibrotic regions (%)*

0

1

2

3

4

5

6

Control

4

4

      

0.36 ± 0.08

CCl4, 2 weeks

4

  

4

    

2.68 ± 0.16

CCl4, 4 weeks

5

   

4

1

  

5.82 ± 0.84#

CCl4, 6 weeks

4

    

2

2

 

12.45 ± 1.16#,##,###

CCl4, 8 weeks

5

     

2

3

13.79 ± 1.99#, ##, ###

  1. *Data are represented as the mean ± SE.
  2. #Significantly different (p < 0.05) from control.
  3. ##Significantly different (p < 0.05) from 2 weeks CCl4 treatment.
  4. ###Significantly different (p < 0.05) from 4 weeks CCl4 treatment.
Back to article page